Stephens initiated coverage of Iqvia with an Overweight rating and $250 price target. The firm says the company has "fulfilled the promise" of combining a leading contract research organization and the largest life science data repository to connect intelligence that advances healthcare. The analyst views the company's Q3 reset, as well as the recent outline of "reasonably conservative" fiscal 2025 and long-term growth frameworks, as creating an attractive setup "for a well-run industry bellwether."
IQVIA continues to outperform earnings expectations, despite a 14% stock decline, driven by concerns of a CRO industry slowdown and reduced early-stage R&D spending. Q3 results show strong performance with $3.9B revenue, 14.1% EPS growth, and a $31.1B backlog, reinforcing long-term growth potential. Analysts project slower CRO growth, but IQVIA's leadership, consistent earnings, and long-term revenue estimates of $28.45B by 2033 support a bullish outlook.
IQV is known for its innovative use of technology and data analytics.
Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
While the top- and bottom-line numbers for IQVIA (IQV) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
IQVIA Holdings Inc. (NYSE:IQV ) Q3 2024 Results Conference Call October 31, 2024 9:00 AM ET Company Participants Kerri Joseph - Senior Vice President, Investor Relations & Treasury Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlman - Executive Vice President and Chief Financial Officer Eric Sherbet - Executive Vice President and General Counsel Mike Fedock - Senior Vice President, Financial Planning and Analysis Gustavo Peroni - Senior Director, Investor Relations Conference Call Participants Ann Hynes - Mizuho Shlomo Rosenbaum - Stifel Anne Samuel - JP Morgan Luke Sergott - Barclays Bank Justin Bowers - Deutsche Bank David Windley - Jefferies Elizabeth Anderson - Evercore ISI Michael Cherny – Leerink Partners Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Third Quarter 2024 Earnings Conference Call.
Strength in the Research and Development, and Technology and Analytics segments drives IQV's top line in the third quarter of 2024.
Contract research firm IQVIA lowered its annual revenue forecast on Thursday, due to delays in two clinical trials as one of its clients faces logistical challenges.
IQVIA Holdings (IQV) came out with quarterly earnings of $2.84 per share, beating the Zacks Consensus Estimate of $2.81 per share. This compares to earnings of $2.49 per share a year ago.
IQV's TAS and RD&S revenues are anticipated to have increased, while CSMS revenues are likely to have dipped in the third quarter of 2024.
Besides Wall Street's top -and-bottom-line estimates for IQVIA (IQV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.